Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | IDE | P14735 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HLCS | P50747 | 6/20 | 0.50 |
| ▸ | FGF1 | P05230 | 1/20 | 0.46 |
| ▸ | FGF2 | P09038 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27849533 | 0.88 | TDP1 (0.56) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL1270497 | 0.85 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL17727882 | 0.83 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL28434108 | 0.78 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL22290232 | 0.75 | TDP1 (0.82) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20500199 | 0.75 | TDP1 (0.58) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20280629 | 0.75 | TDP1 (0.58) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL27832339 | 0.74 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21176811 | 0.74 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21114407 | 0.74 | TDP1 (0.81) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | claimed |
| CN-111712236-A | Compositions comprising lipid-based nanoparticles for the treatment of diabetes | SDG公司 | 2020-09-25 | — | — | CN | claimed |
| CN-110612114-A | Lipid-based nanoparticles with enhanced stability | SDG公司 | 2019-12-24 | — | — | CN | claimed |
| CN-101237854-B | Lipid construct for delivery of insulin to a mammal | SDG INC | 2013-03-27 | — | — | CN | claimed |
| CN-101237854-A | Lipid construct for delivery of insulin to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | claimed |
| CN-101237855-A | Lipid construct for delivery of interferon to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | claimed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| CN-111712236-A | Compositions comprising lipid-based nanoparticles for the treatment of diabetes | SDG公司 | 2020-09-25 | — | — | CN | disclosed |
| CN-110612114-A | Lipid-based nanoparticles with enhanced stability | SDG公司 | 2019-12-24 | — | — | CN | disclosed |
| CN-101237854-B | Lipid construct for delivery of insulin to a mammal | SDG INC | 2013-03-27 | — | — | CN | disclosed |
| CN-101237855-A | Lipid construct for delivery of interferon to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | disclosed |
| CN-101237854-A | Lipid construct for delivery of insulin to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.